WaveMan
WaveMan · Company
AGIO · Agios Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AGIO Agios Pharmaceuticals (AGIO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001439222
Quote by TradingView
Congress · 1Form 144 · 4
Insider buyers, 180 days
0
Funds added, last quarter
135
13F, latest reported quarter
Conversions, 180 days
13
Codes C/M, not in net · $49.7K priced

What the filings say about AGIO

Insiders, 180 days
-$1.1M net sold
1 seller · 50% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-08-20
Planned sales (Form 144), 90 days
$1.3M
4 notices

Agios Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, AGIOS PHARMACEUTICALS, INC. insiders sold a net $1.1M of stock across 148 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Gheuens Sarah
Chief Medical Officer
SELL
2026-10-23 SECtraded 2026-10-22
500
$18.8K
+3.2%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Oct 21, 2026.
  • The trade is 0.9% of the 54,645 shares held after it.
  • No other insider sold within 30 days.
  • 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Gheuens Sarah sold about $18.8K of AGIO under a 10b5-1 plan on Oct 22, 2026; 135 funds added in the latest 13F quarter.
Gheuens Sarah
Chief Medical Officer
SELL
2026-10-23 SECtraded 2026-10-21
1,489
$55.9K
+3.2%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Aug 4, 2026.
  • The trade is 2.7% of the 54,645 shares held after it.
  • No other insider sold within 30 days.
  • 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Gheuens Sarah sold about $55.9K of AGIO under a 10b5-1 plan on Oct 21, 2026; 135 funds added in the latest 13F quarter.
Gheuens Sarah
Chief Medical Officer
SELL
2026-08-06 SECtraded 2026-08-04
30,000
$914.4K
+17.8%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Jul 1, 2026.
  • The trade is 54.9% of the 54,645 shares held after it.
  • No other insider sold within 30 days.
  • 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Gheuens Sarah sold about $914.4K of AGIO on Aug 4, 2026, the largest insider sale at the company since 2024; 135 funds added in the latest 13F quarter.
Gheuens Sarah
Chief Medical Officer
SELL
2026-07-02 SECtraded 2026-07-01
4,007
$150.5K
+1.7%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Apr 2, 2026.
  • The trade is 4.7% of the 84,645 shares held after it.
  • No other insider sold within 30 days.
  • 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Gheuens Sarah sold about $150.5K of AGIO on Jul 1, 2026; 135 funds added in the latest 13F quarter.
Burns James William
Chief Legal Officer
SELL
2026-04-06 SECtraded 2026-04-02
3,280
$113.8K
+8.3%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Mar 2, 2026.
  • The trade is 6.7% of the 49,306 shares held after it.
  • 6 other insiders sold within 30 days.
  • 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Burns James William sold about $113.8K of AGIO on Apr 2, 2026; 6 other insiders sold within 30 days and 135 funds added in the latest 13F quarter.
148 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 143 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.1M over 180 days
-$989.0K over 90 days
below 63% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
135 funds bought in last quarter
more than 79% of Pharma & Biotech
Revenue
+48.0% year over year
more than 76% of Pharma & Biotech
Margin
-764.0% net margin
below 82% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
14.0% of the float short (float per yahoo 2026-10-26) · 6.4 days to cover · settled 2026-09-30
more than 77% of Pharma & Biotech
What changed in the last 30 days
Oct 26Officer SARAH GHEUENS filed to sell $296.5K by Oct 26 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 23Chief Medical Officer Gheuens Sarah sold $74.6K under a 10b5-1 plan (2 trades, Oct 21 to Oct 22)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 22Officer SARAH GHEUENS filed to sell $18.8K by Oct 22 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 21Officer SARAH GHEUENS filed to sell $55.9K by Oct 21 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch AGIO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-9.6%12M
-47%-29%-10%+8%2025-102025-122026-022026-042026-062026-082026-10 2026-08-04 · Gheuens Sarah sold $914.4K2026-04-02 · Goff Brian sold $432.9K2025-12-30 · Goff Brian sold $337.9K2026-03-02 · Goff Brian sold $239.4K2026-04-02 · Goff Brian sold $228.9K2026-03-02 · Goff Brian sold $171.4K2025-12-30 · Goff Brian sold $168.8K2026-03-03 · Washburn Theodore James Jr. sold $152.3K2026-07-01 · Gheuens Sarah sold $150.5K2025-10-27 · Gheuens Sarah sold $145.0K2026-04-02 · Burns James William sold $113.8K2026-04-02 · Milanova Tsveta sold $113.2K2026-03-02 · Goff Brian sold $112.1K2026-04-02 · Jones Cecilia sold $109.0K2025-11-11 · Gheuens Sarah sold $107.4K2026-04-02 · Viswanadhan Krishnan sold $102.7K2026-04-02 · Gheuens Sarah sold $102.0K2026-03-05 · Viswanadhan Krishnan sold $82.3K2025-12-30 · Burns James William sold $79.4K2025-12-30 · Gheuens Sarah sold $79.4K2025-12-30 · Milanova Tsveta sold $79.4K2025-12-30 · Jones Cecilia sold $79.4K2026-01-05 · Milanova Tsveta sold $77.6K2026-10-21 · Gheuens Sarah sold $55.9K2026-03-02 · Burns James William sold $48.7K2026-03-02 · Gheuens Sarah sold $48.7K2026-03-02 · Jones Cecilia sold $48.7K2026-03-02 · Milanova Tsveta sold $48.7K2026-03-02 · Jones Cecilia sold $45.6K2026-03-02 · Burns James William sold $34.4K2026-03-02 · Gheuens Sarah sold $34.4K2026-03-02 · Jones Cecilia sold $34.4K2026-03-02 · Milanova Tsveta sold $34.4K2026-03-02 · Burns James William sold $33.7K2026-03-02 · Washburn Theodore James Jr. sold $23.1K2026-03-02 · Washburn Theodore James Jr. sold $21.1K2026-03-02 · Washburn Theodore James Jr. sold $20.2K2026-10-22 · Gheuens Sarah sold $18.8K2026-03-02 · Jones Cecilia sold $17.2K2025-11-12 · Scadden David sold $8.8K2025-10-30 · Gheuens Sarah sold $8.8K2026-10-26 · SARAH GHEUENS filed to sell $296.5K2026-10-22 · SARAH GHEUENS filed to sell $18.8K2026-10-21 · SARAH GHEUENS filed to sell $55.9K2026-08-04 · SARAH GHEUENS filed to sell $914.3K2026-07-01 · Gheuens Sarah filed to sell $150.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AGIO: institutional holders (13F)

13F holdings, latest reported quarter
Lynx1 Capital Management LP
6,817,874 sh
$253.0M
BlackRock, Inc.
6,455,997 sh
$239.6M
FARALLON CAPITAL MANAGEMENT, L.L.C.
5,917,400 sh
$219.6M
STATE STREET CORP
3,533,633 sh
$131.1M
D. E. Shaw & Co., Inc.
3,107,005 sh
$115.3M

Congress trades in AGIO

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Gilbert Cisneros
Bought 2026-08-20 · disclosed 21 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-12-11 · disclosed 32 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-04-17 · disclosed 19 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-01-29 · disclosed 13 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AGIO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
SARAH GHEUENS
Filed 2026-10-26
$296.5K
SARAH GHEUENS
Filed 2026-10-22
$18.8K
SARAH GHEUENS
Filed 2026-10-21
$55.9K
SARAH GHEUENS
Filed 2026-08-04
$914.3K
Gheuens Sarah
Filed 2026-07-01
$150.5K

AGIO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Etf
$1.4M position · as of 2026-07-31
1.4%
AMG GW&K Small Cap Value Fund
$2.7M position · as of 2026-06-30
1.1%
AlphaCentric Life Sciences and Healthcare Fund
$526.0K position · as of 2026-06-30
1.1%
ALPS Medical Breakthroughs ETF
$1.8M position · as of 2026-05-31
1.1%
AMG GW&K Small/Mid Cap Growth Fund
$457.4K position · as of 2026-07-31
1.1%
AMG GW&K Small Cap Core Fund
$7.2M position · as of 2026-06-30
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
26 registered trials, 16 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Phase 1
2 active
5
Phase 2
3 active
8
Phase 3
7 active
1
Phase 4
1 active
3
Not applicable
1 active
2
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Brian Goff
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$6.8M
$13.0M
$2.5M
-24%
-9%
2023
$3.4M
$2.2M
$2.4M
-49%
-8%
2021
$6.5M
$1.5M
$2.2M
-24%
-1%
2020
$7.6M
$4.3M
$2.4M
-9%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.1M sold by insiders over 180 days, 135 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $1.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AGIO financials

Revenue growth
+48.0%
XBRL, annual
Net margin
-764.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$98.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-418.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$365.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-34.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-31.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-37.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-16.1%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$54.0M$36.5M$26.8M$14.2M
Operating income-$472.1M-$425.7M-$391.5M-$389.0M
Net income-$413.0M$674.0M-$352.0M-$232.0M
EPS (diluted)-7.1211.64-6.33-4.23
Operating cash flow-$373.0M-$389.8M-$296.1M-$309.5M
Cash$89.1M$76.2M$88.2M$139.3M
SEC XBRL, fiscal years, as known on 2026-10-28

AGIO Stock Sonar score 5/7 axes

Find similar shapesCompare

AGIO ranks highest on profitability (62nd percentile) and institutional and government (59th), and lowest on insider conviction (18th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
62
Inputs
  • Return on equity-34.4% · 64 pct, sector of 545
  • Return on assets-31.9% · 59 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-37.6% · 62 pct, sector of 576
Growth
40
Inputs
  • Revenue growth, YoY+48.0% · 76 pct, sector of 505
  • Backlog growth, YoY-93.6% · 5 pct, sector of 40
Insider conviction
18
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.1M · 35 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
59
Inputs
  • Funds adding, latest quarter135 · 79 pct, sector of 698
  • Congress net buyers, 365d1 · 60 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$170K · 36 pct, sector of 133
Risk and compliance
23
Inputs
  • Short interest, % of float+14.0% · 27 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+19.1% · 19 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AGIO filings, in plain words

Are Agios Pharmaceuticals insiders buying or selling AGIO?

In the 180 days to 2026-10-28, Agios Pharmaceuticals insiders were net sellers, a net $1.1M across purchases and sales reported on Form 4, by 1 seller.

Have members of Congress traded AGIO?

Yes. In the year to 2026-10-28, 1 House member disclosed buying AGIO and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-08-20.

Are there planned insider sales of AGIO?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.3M of stock; the latest, by SARAH GHEUENS, was filed 2026-10-26.

Read the full summary

In the 180 days to 2026-10-28, Agios Pharmaceuticals insiders were net sellers of AGIO, a net $1.1M across purchases and sales reported on Form 4 by 1 seller. 50% of the 4 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying AGIO and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-08-20. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies